Type 2 diabetes, cognition, and dementia in older adults: Toward a precision health approach

Diabetes Spectrum

Volumn 29, Issue 4, 2016, Pages 210-219

  Cholerton, Brenna ^a   Baker, Laura D ^b   Montine, Thomas J ^a   Craft, Suzanne ^b  

^a STANFORD UNIVERSITY   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN;

AGED; AGING; ALZHEIMER DISEASE; ARTICLE; COGNITION; COGNITIVE DEFECT; DEMENTIA; DIET; ENVIRONMENTAL FACTOR; EXERCISE; HEREDITY; HIGH RISK POPULATION; HUMAN; HYPERINSULINEMIA; LEARNING; MEMORY; MULTIINFARCT DEMENTIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PERSONALIZED MEDICINE; RISK REDUCTION; UNITED STATES;

EID: 85009074847     PISSN: 10409165     EISSN: 19447353     Source Type: Journal    
DOI: 10.2337/ds16-0041     Document Type: Article

References (96)

1. Hassing LB, Grant MD, Hofer SM, et al. Type 2 diabetes mellitus contributes to cognitive decline in old age: a longitudinal population-based study. J Int Neuropsychol Soc 2004;10:599-607
2. Strachan MW. R. D. Lawrence Lecture 2010: The brain as a target organ in type 2 diabetes: exploring the links with cognitive impairment and dementia. Diabet Med 2011;28:141-147
3. Yaffe K, Blackwell T, Kanaya AM, Davidowitz N, Barrett-Connor E, Krueger K. Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. Neurology 2004;63:658-663
4. Shaik MA, Chan QL, Xu J, et al. Risk factors of cognitive impairment and brief cognitive tests to predict cognitive performance determined by a formal neuropsychological evaluation of primary health care patients. J Am Med Dir Assoc 2016;17:343-347
5. Tilvis RS, Kahonen-Vare MH, Jolkkonen J, Valvanne J, Pitkala KH, Strandberg TE. Predictors of cognitive decline and mortality of aged people over a 10-year period. J Gerontol A Biol Sci Med Sci 2004;59:268-274
6. Mehrabian S, Raycheva M, Gateva A, et al. Cognitive dysfunction profile and arterial stiffness in type 2 diabetes. J Neurol Sci 2012;322:152-156
7. McCrimmon RJ, Ryan CM, Frier BM. Diabetes and cognitive dysfunction. Lancet 2012;379:2291-2299
8. McFall GP, Wiebe SA, Vergote D, Anstey KJ, Dixon RA. Alzheimer's genetic risk intensifies neurocognitive slowing associated with diabetes in non-demented older adults. Alzheimer's Dement 2015;1:395-402
9. Yaffe K, Peltz CB, Ewing SK, et al. Longterm cognitive trajectories and mortality in older women. J Gerontol A Biol Sci Med Sci 2016;71:1074-1080
10. Goveas JS, Rapp SR, Hogan PE, et al. Predictors of optimal cognitive aging in 80+ women: the Women's Health Initiative Memory Study. J Gerontol A Biol Sci Med Sci 2016;71(Suppl. 1):S62-S71
11. Banks WA, Jaspan JB, Kastin AJ. Selective, physiological transport of insulin across the blood-brain barrier: novel demonstration by species-specific radioimmunoassays. Peptides 1997;18:1257-1262
12. Lee J, Kim K, Yu SW, Kim EK. Wnt3a upregulates brain-derived insulin by increasing NeuroD1 via Wnt/beta-catenin signaling in the hypothalamus. Mol Brain 2016;9:24
13. Ghasemi R, Haeri A, Dargahi L, Mohamed Z, Ahmadiani A. Insulin in the brain: sources, localization and functions. Mol Neurobiol 2013;47:145-171
14. Adzovic L, Lynn AE, D'Angelo HM, et al. Insulin improves memory and reduces chronic neuroinflammation in the hippocampus of young but not aged brains. J Neuroinflammation 2015;12:63
15. Park CR, Seeley RJ, Craft S, Woods SC. Intracerebroventricular insulin enhances memory in a passive-avoidance task. Physiol Behav 2000;68:509-514
16. Freiherr J, Hallschmid M, Frey WH 2nd, et al. Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence. CNS Drugs 2013;27:505-514
17. Zhao W, Chen H, Xu H, et al. Brain insulin receptors and spatial memory: correlated changes in gene expression, tyrosine phosphorylation, and signaling molecules in the hippocampus of water maze trained rats. J Biol Chem 1999;274:34893-34902
18. Schwartz MW, Figlewicz DF, Kahn SE, Baskin DG, Greenwood MR, Porte D Jr. Insulin binding to brain capillaries is reduced in genetically obese, hyperinsulinemic Zucker rats. Peptides 1990;11:467-472
19. Moran C, Phan TG, Chen J, et al. Brain atrophy in type 2 diabetes: regional distribution and influence on cognition. Diabetes Care 2013;36:4036-4042
20. Brundel M, Kappelle LJ, Biessels GJ. Brain imaging in type 2 diabetes. Eur Neuropsychopharmacol 2014;24:1967-1981
21. Vanhanen M, Koivisto K, Kuusisto J, et al. Cognitive function in an elderly population with persistent impaired glucose tolerance. Diabetes Care 1998;21:398-402
22. Gudala K, Bansal D, Schifano F, Bhansali A. Diabetes mellitus and risk of dementia: a meta-analysis of prospective observational studies. J Diabetes Invest 2013;4:640-650
23. Haroon NN, Austin PC, Shah BR, Wu J, Gill SS, Booth GL. Risk of dementia in seniors with newly diagnosed diabetes: a population-based study. Diabetes Care 2015;38:1868-1875
24. van de Vorst IE, Koek HL, de Vries R, Bots ML, Reitsma JB, Vaartjes I. Effect of vascular risk factors and diseases on mortality in individuals with dementia: a systematic review and meta-analysis. J Am Geriatr Soc 2016;64:37-46
25. Mittal K, Katare DP. Shared links between type 2 diabetes mellitus and Alzheimer's disease: a review. Diabetes Metab Syndr 2016;pii:S1871-4021: 30070-9. Electronically published ahead of print (DOI: 10.1016/j.dsx.2016.01.021)
26. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology 1999;53:1937-1942
27. Maher PA, Schubert DR. Metabolic links between diabetes and Alzheimer's disease. Expert Rev Neurother 2009;9:617-630
28. Janson J, Laedtke T, Parisi JE, O'Brien P, Petersen RC, Butler PC. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 2004;53:474-481
29. Ostergaard SD, Mukherjee S, Sharp SJ, et al. Associations between potentially modifiable risk factors and Alzheimer disease: a Mendelian randomization study. PLoS Med 2015;12:e1001841; discussion e1001841
30. Chung SJ, Kim MJ, Kim J, et al. Association of type 2 diabetes GWAS loci and the risk of Parkinson's and Alzheimer's diseases. Parkinsonism Relat Disord 2015;21:1435-1440
31. Walter S, Marden JR, Kubzansky LD, et al. Diabetic phenotypes and late-life dementia risk: a mechanism-specific Mendelian randomization study. Alzheimer Dis Assoc Disord 2016;30:15-20
32. Hao K, Di Narzo AF, Ho L, et al. Shared genetic etiology underlying Alzheimer's disease and type 2 diabetes. Mol Aspects Med 2015;43-44,66-76
33. Gasparini L, Gouras GK, Wang R, et al. Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. J Neurosci 2001;21:2561-2570
34. Ahmed S, Mahmood Z, Zahid S. Linking insulin with Alzheimer's disease: emergence as type III diabetes. Neurol Sci 2015;36:1763-1769
35. Townsend M, Mehta T, Selkoe DJ. Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. J Biol Chem 2007;282:33305-33312
36. De Felice FG, Vieira MN, Bomfim TR, et al. Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci U S A 2009;106:1971-1976
37. Hong M, Lee VM. Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. J Biol Chem 1997;272:19547-19553
38. Schubert M, Brazil DP, Burks DJ, et al. Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. J Neurosci 2003;23:7084-7092
39. Schubert M, Gautam D, Surjo D, et al. Role for neuronal insulin resistance in neurodegenerative diseases. Proc Natl Acad Sci U S A 2004;101:3100-3105
40. Vincent AM, Brownlee M, Russell JW. Oxidative stress and programmed cell death in diabetic neuropathy. Ann N Y Acad Sci 2002;959:368-383
41. Knezovic A, Osmanovic-Barilar J, Curlin M, et al. Staging of cognitive deficits and neuropathological and ultrastructural changes in streptozotocin-induced rat model of Alzheimer's disease. J Neural Transm 2015;122:577-592
42. Roberts RO, Knopman DS, Cha RH, et al. Diabetes and elevated hemoglobin A1c levels are associated with brain hypometabolism but not amyloid accumulation. J Nuclear Med 2014;55:759-764
43. Moran C, Beare R, Phan TG, Bruce DG, Callisaya ML, Srikanth V; Alzheimer's Disease Neuroimaging I: Type 2 diabetes mellitus and biomarkers of neurodegeneration. Neurology 2015;85:1123-1130
44. Kapasi A, Schneider JA. Vascular contributions to cognitive impairment, clinical Alzheimer's disease, and dementia in older persons. Biochim Biophys Acta 2016;1862:878-886
45. Reijmer YD, Leemans A, Brundel M, Kappelle LJ, Biessels GJ, Utrecht Vascular Cognitive Impairment Study Group. Disruption of the cerebral white matternetwork is related to slowing of information processing speed in patients with type 2 diabetes. Diabetes 2013;62:2112-2115
46. Reijmer YD, Brundel M, de Bresser J, Kappelle LJ, Leemans A, Biessels GJ, Utrecht Vascular Cognitive Impairment Study Group. Microstructural white matter abnormalities and cognitive functioning in type 2 diabetes: a diffusion tensor imaging study. Diabetes Care 2013;36:137-144
47. Zhang JH, Xu HZ, Shen QF, et al. Nepsilon-(carboxymethyl)-lysine, white matter, and cognitive function in diabetes patients. Can J Neurol Sci 2016:43:518-522
48. Yau PL, Javier D, Tsui W, et al. Emotional and neutral declarative memory impairments and associated white matter microstructural abnormalities in adults with type 2 diabetes. Psychiatry Res 2009;174:223-230
49. Chatterjee S, Peters SA, Woodward M, et al. Type 2 diabetes as a risk factor for dementia in women compared with men: a pooled analysis of 2.3 million people comprising more than 100,000 cases of dementia. Diabetes Care 2016;39:300-307
50. Flanagan M, Larson EB, Latimer CS, et al. Clinical-pathologic correlations in vascular cognitive impairment and dementia. Biochim Biophys Acta 2016;1862:945-951
51. Kamal A, Biessels GJ, Gispen WH, Ramakers GM. Synaptic transmission changes in the pyramidal cells of the hippocampus in streptozotocin-induced diabetes mellitus in rats. Brain Res 2006;1073-1074:276-280
52. Hishikawa N, Fukui Y, Sato K, Yamashita T, Ohta Y, Abe K. Clinical features of incidental mild cognitive impairment and dementia in a population-based study. Geriatr Gerontol Int 2016. Electronically published ahead of print (DOI: 10.1111/ggi.12778)
53. Hishikawa N, Fukui Y, Sato K, et al. Cognitive and affective functions in Alzheimer's disease patients with metabolic syndrome. Eur J Neurol 2016;23:339-345
54. Deschaintre Y, Richard F, Leys D, Pasquier F. Treatment of vascular risk factors is associated with slower decline in Alzheimer disease. Neurology 2009;73:674-680
55. Cholerton B, Larson EB, Quinn JF, et al. Precision medicine: clarity for the complexity of dementia. Am J Pathol 2016;186:500-506
56. Masdeu JC, Kreisl WC, Berman KF. The neurobiology of Alzheimer disease defined by neuroimaging. Curr Opin Neurol 2012;25:410-420
57. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dement 2011;7:280-292
58. Tolppanen AM, Solomon A, Soininen H, Kivipelto M. Midlife vascular risk factors and Alzheimer's disease: evidence from epidemiological studies. J Alzheimer's Dis 2012;32:531-540
59. Willette AA, Johnson SC, Birdsill AC, et al. Insulin resistance predicts brain amyloid deposition in late middle-aged adults. Alzheimer's Dement 2015;11:504-510
60. Solfrizzi V, Panza F, Frisardi V, et al. Diet and Alzheimer's disease risk factors or prevention: the current evidence. Expert Rev Neurother 2011;11:677-708
61. Schroeder JE, Richardson JC, Virley DJ. Dietary manipulation and caloric restriction in the development of mouse models relevant to neurological diseases. Biochim Biophys Acta 2010;1802:840-846
62. Takechi R, Galloway S, Pallebage-Gamarallage MM, Lam V, Mamo JC. Dietary fats, cerebrovasculature integrity and Alzheimer's disease risk. Prog Lipid Res 2010;49:159-170
63. Smith PJ, Blumenthal JA. Diet and neurocognition: review of evidence and methodological considerations. Curr Aging Sci 2010;3:57-66
64. Bayer-Carter JL, Green PS, Montine TJ, et al. Diet intervention and cerebrospinal fluid biomarkers in amnestic mild cognitive impairment. Arch Neurol 2011;68:743-752
65. Archer T. Physical exercise alleviates debilities of normal aging and Alzheimer's disease. Acta Neurol Scand 2011;123:221-238
66. Kramer AF, Hahn S, Cohen NJ, et al. Ageing, fitness and neurocognitive function. Nature 1999;400:418-419
67. Kramer AF, Erickson KI, Colcombe SJ. Exercise, cognition, and the aging brain. J Appl Physiol 2006;101:1237-1242
68. Baker LD, Frank LL, Foster-Schubert K, et al. Aerobic exercise improves cognition for older adults with glucose intolerance, a risk factor for Alzheimer's disease. J Alzheimer's Dis 2010;22:569-579
69. Lautenschlager NT, Cox KL, Flicker L, et al. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. JAMA 2008;300:1027-1037
70. Geda YE, Roberts RO, Knopman DS, et al. Physical exercise, aging, and mild cognitive impairment: a population-based study. Arch Neurol 2010;67:80-86
71. Andel R, Crowe M, Pedersen NL, Fratiglioni L, Johansson B, Gatz M. Physical exercise at midlife and risk of dementia three decades later: a population-based study of Swedish twins. J Gerontol A Biol Sci Med Sci 2008;63:62-66
72. Liang KY, Mintun MA, Fagan AM, et al. Exercise and Alzheimer's disease biomarkers in cognitively normal older adults. Ann Neurol 2010;68:311-318
73. Born J, Lange T, Kern W, McGregor GP, Bickel U, Fehm HL. Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci 2002;5:514-516
74. Francis GJ, Martinez JA, Liu WQ, et al. Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy. Brain 2008;131:3311-3334
75. Thorne RG, Pronk GJ, Padmanabhan V, Frey WH 2nd. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 2004;127:481-496
76. Benedict C, Hallschmid M, Hatke A, et al. Intranasal insulin improves memory in humans. Psychoneuroendocrinology 2004;29:1326-1334
77. Reger MA, Watson GS, Green PS, et al. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J Alzheimer's Dis 2008;13:323-331
78. Reger MA, Watson GS, Frey WH 2nd, et al. Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging 2006;27:451-458
79. Claxton A, Baker LD, Hanson A, et al. Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia. J Alzheimer's Dis 2015;44:897-906
80. Craft S, Baker LD, Montine TJ, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 2012;69:29-38
81. Reger MA, Watson GS, Green PS, et al. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 2008;70:440-448
82. Ng TP, Feng L, Yap KB, Lee TS, Tan CH, Winblad B. Long-term metformin usage and cognitive function among older adults with diabetes. J Alzheimer's Dis 2014;41:61-68
83. Mostafa DK, Ismail CA, Ghareeb DA. Differential metformin dose-dependent effects on cognition in rats: role of Akt. Psychopharmacology 2016;233:2513-2524
84. Moore EM, Mander AG, Ames D, et al. Increased risk of cognitive impairment in patients with diabetes is associated with metformin. Diabetes Care 2013;36:2981-2987
85. Sonnen JA, Larson EB, Brickell K, et al. Different patterns of cerebral injury in dementia with or without diabetes. Arch Neurol 2009;66:315-322
86. Herath PM, Cherbuin N, Eramudugolla R, Anstey KJ. The effect of diabetes medication on cognitive function: evidence from the PATH Through Life study. Biomed Res Int 2016;2016:7208429
87. Lan LF, Zheng L, Yang X, Ji XT, Fan YH, Zeng JS. Peroxisome proliferator-activated receptor-gamma agonist pioglitazone ameliorates white matter lesion and cognitive impairment in hypertensive rats. CNS Neurosci Ther 2015;21:410-416
88. Kariharan T, Nanayakkara G, Parameshwaran K, et al. Central activation of PPAR-gamma ameliorates diabetes induced cognitive dysfunction and improves BDNF expression. Neurobiol Aging 2015;36:1451-1461
89. Liu LP, Yan TH, Jiang LY, et al. Pioglitazone ameliorates memory deficits in streptozotocin-induced diabetic mice by reducing brain beta-amyloid through PPARgamma activation. Acta Pharmacol Sin 2013;34:455-463
90. Watson GS, Cholerton BA, Reger MA, et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 2005;13:950-958
91. Harrington C, Sawchak S, Chiang C, et al. Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies. Curr Alzheimer Res 2011;8:592-606
92. Gold M, Alderton C, Zvartau-Hind M, et al. Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord 2010;30:131-146
93. Hanyu H, Sato T, Kiuchi A, Sakurai H, Iwamoto T. Pioglitazone improved cognition in a pilot study on patients with Alzheimer's disease and mild cognitive impairment with diabetes mellitus. J Am Geriatr Soc 2009;57:177-179
94. Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T. Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging 2011;32:1626-1633
95. Geldmacher DS, Fritsch T, McClendon MJ, Landreth G. A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease. Arch Neurology 2011;68:45-50
96. Moon JH, Kim HJ, Yang AH, et al. The effect of rosiglitazone on LRP1 expression and amyloid beta uptake in human brain microvascular endothelial cells: a possible role of a low-dose thiazolidinedione for dementia treatment. Int J Neuropsychopharmacol 2012;15:135-142